SOPHARMA AD (94/2023) Completion of the infusion conversion procedure of "Biopharm Engineering" AD
Report no 94/2023
- 23.08.2023, 14:21
- Kategoria: Biznes i finanse
- Źródło: ESPI
Sopharma AD-BG11SOSOBT18-SOPHARMA
-
-
SOPHARMA AD (93/2023) Sales revenues for July 2023
Report no 93/2023- 21.08.2023, 13:41
- Kategoria: Biznes i finanse
- Źródło: ESPI
-
SOPHARMA AD (91/2023) Individual financial report according to IFRS as at 30 June 2023
Report no 91/2023- 31.07.2023, 13:02
- Kategoria: Biznes i finanse
- Źródło: ESPI
-
SOPHARMA AD (90/2023) "Sopharma" AD starts the payment of the 2022 dividend on July 31, 2023
Report no 90/2023- 26.07.2023, 13:04
- Kategoria: Biznes i finanse
- Źródło: ESPI
-
SOPHARMA AD (89/2023) Sales revenues for June 2023
Report no 89/2023- 20.07.2023, 13:05
- Kategoria: Biznes i finanse
- Źródło: ESPI
-
SOPHARMA AD (88/2023) Initiation of negotiations for potential acquisition of Pharmanova, Republic of Serbia
Report no 88/2023- 14.07.2023, 16:13
- Kategoria: Biznes i finanse
- Źródło: ESPI
-
SOPHARMA AD (87/4072023) Conveining Extraordinary General Meeting for 4 August 2023
Report no 87/4072023- 04.07.2023, 18:45
- Kategoria: Biznes i finanse
- Źródło: ESPI
-
SOPHARMA AD (86/2023) Notification from "Telso" AD under Art. 19 of Regulation (EU) No 596/2014 of 30 June 2023.
Report no 86/2023- 03.07.2023, 13:12
- Kategoria: Biznes i finanse
- Źródło: ESPI
-
SOPHARMA AD (85/2023) Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of 30 June 2023.
Report no 85/2023- 03.07.2023, 12:57
- Kategoria: Biznes i finanse
- Źródło: ESPI
